Cooper Standard Second Quarter Gross Profit Ramps Higher; Further Margin Expansion Expected in Second Half of the Year
Prnewswire· 2024-08-02 04:44
NORTHVILLE, Mich., Aug. 1, 2024 /PRNewswire/ -- Cooper-Standard Holdings Inc. (NYSE: CPS) today reported results for the second quarter 2024. Second Quarter 2024 Summary Gross profit totaled $82.9 million, an increase of 6.7% compared to second quarter 2023 Net loss of $76.2 million, or $(4.34) per diluted share, was negatively impacted by a one-time non-cash pension settlement charge and restructuring expense Adjusted net loss of $11.3 million, or $(0.64) per diluted share, improved by 43.5% vs. the second ...
Sandstorm Gold Royalties Announces 2024 Second Quarter Results
Prnewswire· 2024-08-02 04:44
VANCOUVER, BC, Aug. 1, 2024 /PRNewswire/ - Sandstorm Gold Ltd. ("Sandstorm Gold Royalties", "Sandstorm" or the "Company") (NYSE: SAND) (TSX: SSL) has released its financial results for the second quarter ended June 30, 2024 (figures in U.S. dollars unless otherwise indicated). Financial Highlights $41.4 million of revenue compared to $49.8 million in Q2 2023; 17,414 attributable gold equivalent ounces1 compared to 24,504 ounces in Q2 2023; $32.6 million in cash flows from operating activities, excluding cha ...
MasTec Announces Second Quarter 2024 Financial Results and Updates Guidance for the Year
Prnewswire· 2024-08-02 04:37
Record Second Quarter 2024 Revenue of $3.0 Billion Second Quarter 2024 Diluted Earnings Per Share of $0.43 and Adjusted Diluted Earnings Per Share of $0.96, $0.08 Above Expectations Second Quarter 2024 GAAP Net Income of $43.8 Million and Adjusted EBITDA of $267.8 Million, $7.8 Million Above Expectations 18-month Backlog as of June 30, 2024 of $13.3 Billion Increased $501 Million Sequentially from the First Quarter of 2024 and Represents Record Levels for the Clean Energy and Infrastructure, Power Delivery ...
H&R Block to Release Fiscal 2024 Results on August 15, 2024
Newsfilter· 2024-08-02 04:35
KANSAS CITY, Mo., Aug. 01, 2024 (GLOBE NEWSWIRE) -- H&R Block, Inc. (NYSE:HRB) will report fourth quarter and fiscal 2024 full year results on Thursday, August 15, 2024, after the New York Stock Exchange market close. At that time, a copy of the press release and presentation will be available on the company's investor relations website at https://investors.hrblock.com/. A conference call for analysts, institutional investors, and shareholders will be held at 4:30 p.m. Eastern time on Thursday, August 15, 2 ...
MARA Reports Second Quarter 2024 Results
Newsfilter· 2024-08-02 04:35
- Revenues Increase 78% to $145.1 Million - Fair Market Value Loss of $148.0 Million, Resulting in Net Loss of $199.7 Million, or $0.72 Loss per Diluted Share - Adjusted EBITDA Decreases to a Loss of $85.1 Million Year-Over-Year Comparison Prior Quarter Comparison Metric(1) Q2 2024 Q2 2023 % Δ Q2 2024 Q1 2024 % Δ Fort Lauderdale, FL, Aug. 01, 2024 (GLOBE NEWSWIRE) -- MARA (NASDAQ:MARA) ("MARA" or the "Company"), a global leader in leveraging digital asset compute to support the energy transformation, report ...
AES Reports Record Sales with Data Center Hyperscalers
Prnewswire· 2024-08-02 04:35
文章核心观点 - 公司在第二季度取得了强劲的业绩表现,包括与数据中心客户签署了2.2GW的新协议,并完成了976MW的风电、太阳能和储能项目的建设或收购 [1][5] - 公司预计2024年调整后EBITDA和调整后每股收益将达到指导区间的上半部分,并维持了未来几年的增长目标 [3][6][7] - 公司的业务模式具有很强的抗风险能力,能够确保未来几年的强劲增长 [3] 根据目录分别总结 战略成就 - 公司已与技术客户签署了8.1GW的协议,包括输电和配电、可再生能源电力购买协议(PPA)和零售供应 [5] - 公司的PPA订单量达到12.6GW,其中5.1GW正在建设中 [5] - 公司在第二季度新签署了1GW的长期PPA,并完成了976MW的新项目建设或收购 [5] 财务业绩 - 第二季度公司的调整后EBITDA和调整后每股收益同比分别增长14.6%和81% [4] - 公司预计2024年调整后EBITDA和调整后每股收益将达到指导区间的上半部分 [6][7] - 公司维持了未来几年的调整后EBITDA和调整后每股收益的增长目标 [6][7] 财务状况和展望 - 公司的财务状况良好,流动性充足 [30] - 公司预计未来几年业务将保持强劲增长 [3][6][7]
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
Newsfilter· 2024-08-02 04:30
ROCKVILLE, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it has resubmitted its New Drug Application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease (PD). Supernus believes it has addressed the U.S. Food and Drug Administrat ...
Host Hotels & Resorts Provides Updated Second Quarter 2024 Investor Presentation
Newsfilter· 2024-08-02 04:30
BETHESDA, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Host Hotels & Resorts, Inc. (NASDAQ:HST) (the "Company"), the nation's largest lodging real estate investment trust, today provided an updated investor presentation for second quarter 2024 results. The investor presentation can be found on the Investor Relations section on the Company's website at https://www.hosthotels.com/#key-investors-materials. ABOUT HOST HOTELS & RESORTS Host Hotels & Resorts, Inc. is an S&P 500 company and is the largest lodging real e ...
Greif Announces Sale of Delta Petroleum Company
Newsfilter· 2024-08-02 04:30
DELAWARE, Ohio, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Greif, Inc. (NYSE: GEF, GEF.B), a global leader in industrial packaging products and services, today announced it has sold Delta Petroleum Company, Inc. ("Delta"), a North American filling and logistics services business, to PSC Group LLC, a North American leader in product handling, site logistics, railcar repair, and sustainability services for the petrochemical, refining, and marine industries. "We are happy to have worked with the PSC Group in a transact ...
FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL Treatment
Newsfilter· 2024-08-02 04:30
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Cellectis' CLLS52 (alemtuzumab), an Investigational Medicinal Product (IMP) used as part of the lymphodepletion regimen associated with UCART22, evaluated in the ...